Re-Evaluating the Role of Radiopharmaceuticals in mCRPC

In this activity, based on a series of webinars, experts in the management of mCRPC explore strategies for individualising treatment plans that not only adhere to contemporary, evidence-based best practices, but also address patient needs and preferences. For the complete activity, including supporting material, please visit: www.peervoice.com/FJS861. Presented by: Fred Saad, MD, FRCS, Pedro C. Barata, MD, MSc, FACP, and Mikael Lagström. Learning Objectives: Review clinical trials evaluating the use of radiopharmaceutical agents in combination with other agents, in the early management of mCRPC; Recognise patient-reported experiences, priorities, and goals of care among those diagnosed with mCRPC; Implement communication and empowerment techniques to encourage greater understanding of mCRPC and available treatment options; and Propose individualised treatment plans for the management of mCRPC that align with patient needs and contemporary, evidence-based best practices.